Albert Bourla, Pfizer CEO (John Thys, Pool via AP Images)

No more busi­ness as usu­al: Pfiz­er, Bay­er and Sanofi step up ac­tions against Rus­sia amid grow­ing pres­sure to ex­it

As the Russ­ian in­va­sion of Ukraine en­ters its third week, phar­ma — just like a host of oth­er in­dus­tries — is feel­ing a grow­ing pres­sure to get se­ri­ous about ex­it­ing Rus­sia.

Pfiz­er, Bay­er and Sanofi were among the first to de­clare dra­mat­ic ac­tion on that score, for­mal­iz­ing com­mit­ments that their re­spec­tive CEOs have com­mu­ni­cat­ed in re­cent days in­to writ­ten state­ments.

Bio­phar­ma com­pa­nies across the board have joined an in­ter­na­tion­al cho­rus of voic­es con­demn­ing Rus­sia’s at­tack and sup­port­ing Ukraini­ans. But most have stuck with ei­ther in­ter­nal (fo­cus­ing on their own em­ploy­ees) or hu­man­i­tar­i­an ef­forts (for in­stance, do­nat­ing es­sen­tial med­i­cines to Ukraine) rather than busi­ness or eco­nom­ic ones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.